Moteur de recherche d’entreprises européennes
Financement de l’UE (15 M €) : Biomarqueurs à base de MICROBiome pour prédire la décompensation de la cirrhose du foie et la réponse au traitement Hor01/01/2019 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Biomarqueurs à base de MICROBiome pour prédire la décompensation de la cirrhose du foie et la réponse au traitement
Decompensation of liver cirrhosis and progression towards acute-on-chronic liver failure (ACLF) causes 1.2 million deaths/year. Microbiome is causally involved in cirrhosis progression and is for drugs the first interaction point with the patients. Drugs can alter the microbiome leading to unwanted effects or even facilitating their effects, but the microbiome metabolizes the drugs, shapes their effects and possibly determines the host response to drugs. As each person carries an individual microbiome, insight in these processes should help stratify or even personalize patient health care and treatment. The aims of MICROB-PREDICT are 1) to better understand the role of microbiome and the gut-liver-axis interactome with respect to microbiome functionalities, 2) to identify and validate microbiome-based biomarkers and signatures for personalized prediction of decompensation and ACLF, and response to treatment, 3) to design three new tests as easy-to-use tools and point-of-care, smartphone-connected nanobiosensors, and 4) to validate them in a randomized controlled trial. MICROB-PREDICT will ass????e existing data and samples from major microbiome initiatives in hepatology (12 international studies, >10,000 patients), and enrich them with holistic and in-depth analysis using cutting-edge multi-omics technologies of host and microbiome from different body sites in samples of >1,000 patients collected in a longitudinal manner with sequential visits and controlling for confounders. MICROB-PREDICT results will foster more accurate, personalized risk stratification and significant steps towards personalized treatment of decompensated cirrhosis and ACLF. World-leading microbiome specialists, technology leaders and clinical experts make this a programme of scientific excellence; patient organisations (ELPA) and the European Association for the study of the Liver (EASL) will channel our results into a powerful dissemination, communication and exploitation programme.
| Academisch Ziekenhuis Leiden | 500 500 € |
| BIOBYTE SOLUTIONS GmbH | 290 000 € |
| CONCENTRIS RESEARCH MANAGEMENT GmbH | 535 000 € |
| Commissariat a L Energie Atomique et aux Energies Alternatives | 648 000 € |
| 347 000 € | |
| EUROPEAN Association FOR THE STUDYOF THE LIVER | 56 200 € |
| 2 021 900 € | |
| 2 283 191 € | |
| European Liver Patients Association | 80 000 € |
| Fundacio Institut Catala de Nanociencia i Nanotecnologia | 1 089 400 € |
| Fundacio de Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi i Sunyer | 460 000 € |
| Hospital Clinic de Barcelona | 0,00 € |
| Institut National de Recherche Pour l'Agriculture, l'Alimentation et l'Environnement | 620 000 € |
| JOHANN WOLFGANG GOETHE-UNIVERSITAET FRANKFURT AM MAIN | 126 577 € |
| Katholieke Universiteit Leuven | 620 000 € |
| King's College London | 500 000 € |
| Kobenhavns Universitet | 1 246 100 € |
| MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN e. V. | 996 000 € |
| Region Syddanmark | 887 500 € |
| UNIVERSITAET MUENSTER | 511 132 € |
| Universitat de Barcelona | 224 000 € |
| Universitetet I Oslo | 150 000 € |
| 323 500 € | |
| Vaiomer | 484 000 € |
https://cordis.europa.eu/project/id/825694
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.
Les visualisations de "Academisch Ziekenhuis Leiden - Financement de l’UE (15 M €) : Biomarqueurs à base de MICROBiome pour prédire la décompensation de la cirrhose du foie et la réponse au traitement"
sont mis à disposition par
North Data
et peuvent être réutilisées selon les termes de la licence
Creative Commons CC-BY.
